Novel Anti-Amyloid Slows Cognitive Decline in Phase II Alzheimer Trial
MedPage Today,
Neurology > Alzheimer's Disease Though benefit was limited in 76-week study, specialists see reasons for optimism Donanemab, an…
Neurology > Alzheimer's Disease Though benefit was limited in 76-week study, specialists see reasons for optimism Donanemab, an…
. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges. Mol Neurodegener.